-

Eurofins Scientific Announces the Acquisition of Quasfar, Establishing a Presence in Colombia and Expanding the Presence of Eurofins Laboratories in Latin America

LUXEMBOURG--(BUSINESS WIRE)--The Eurofins network of companies, the global leader in food, environment, pharmaceutical and cosmetic product testing and in discovery pharmacology, forensics, advanced material sciences and agroscience contract research services, announces the completion of the acquisition of Quasfar.

Known as Eurofins Quasfar going forward, the laboratory represents the first Eurofins laboratory in Colombia and is a leading pharmaceutical, veterinary and cosmetic product testing laboratory, with over 26 years of experience, employing over 100 employees. Based in Bogotá, Colombia, the 1,680 m² laboratory is equipped with state-of-the-art testing equipment, technology and information platforms and systems, and is certified in Good Laboratory Practices for pharmaceutical quality control laboratories, under the guidelines of WHO Technical Report Series, No. 957, 2010 44th Report – Annex 1. With a focus on scientific training and R&D, the Quasfar team develops analytical methodologies that respond to customer and regulatory needs, with a commitment to exceptional quality management systems, and good laboratory, bioavailability and bioequivalence practices.

The origins of Eurofins’ presence in Brazil dates back to 2001, when Eurofins Genescan established its presence in Brazil, setting up an office in São Paulo/SP, shortly followed by the opening of a laboratory. Since then, the Eurofins network of companies has continued to expand in Brazil and Latin America, with more than 10 laboratories across 5 LATAM countries now operating across food, environmental, pharmaceutical, agroscience, and clinical diagnostics testing, as well as providing special consultancy services and audits.

With a proven history in providing support to the pharmaceutical sector in Colombia, the acquisition of Quasfar strengthens the Eurofins network’s support to the pharmaceutical industry in Latin America, through the provision of R&D and supporting evaluation in the early stages of pharmaceutical product development, with the highest quality standards and TAT.

Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. With over 61,000 staff across a network of ca. 900 laboratories in 61 countries, Eurofins offers a portfolio of over 200,000 analytical methods.

Eurofins Shares are listed on Euronext Paris Stock Exchange.

Eurofins Quasfar:
Bogotá- based Eurofins Quasfar is a state-of-the-art laboratory, offering a broad analytical testing portfolio to the pharmaceutical, veterinary and cosmetic segments, and recognised for its expertise in developing complex analytical methodologies with diverse techniques to meet customer and regulatory needs.

Contacts

Eurofins Scientific

BOURSE:ERF

Release Versions

Contacts

More News From Eurofins Scientific

Eurofins MET Laboratories Opens New Safety, EMC, Wireless, and Renewable Energy Laboratory in the Boston Tech Corridor

BOSTON--(BUSINESS WIRE)--Eurofins MET Laboratories, part of the Eurofins Electrical & Electronics global network, announces the opening of its new state-of-the-art 60,000-square-foot testing laboratory in Littleton, Massachusetts – a prime location in the Boston innovation corridor. Positioned at the epicenter of New England's med-tech, wireless innovation, clean energy, and advanced electronics ecosystem, the capabilities of this laboratory further position Eurofins MET Laboratories as the...

Eurofins Scientific SE: Weekly Report on Share Repurchases from 26th January to 30th January 2026

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 26/01/2026 FR0014000MR3 5 000 70.7336 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 27/01/2026 FR0014000MR3 5 000 70.9680 XPAR EUROFINS SCIENTIFIC 529900JEHFM47...

Eurofins Delivers FY 2025 Objectives with a 24% EPS Growth, Accelerating Organic Revenue Growth, Margin Expansion, and Higher Free Cash Flow and Confirms Its 2027 Objectives

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins (Paris:ERF) pre-publishes below its preliminary unaudited consolidated financial results for the year ending 31 December 2025, as described in the first paragraphA of the Business Review section of this press release. Financial highlights in FY 2025 Basic EPS8 grew 24% to €2.31 in 2025 vs €1.87 in 2024, driven by a strong operating performance and starting to reap the benefits from Eurofins five-year investment programme in its hub and spok...
Back to Newsroom